American Vietnamese Biotech

American Vietnamese Biotech EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of American Vietnamese Biotech (AMV.VN) as of Oct 23, 2026 is 0.72. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -2.75 — a change of -126.25% (higher).

EV/FCF

0.72

YoY

-126.25%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of American Vietnamese Biotech is 2024 0.72 . EV/FCF (Enterprise Value to Free Cash Flow) of American Vietnamese Biotech was 2023 -2.75 . It decreases by -126.25% higher compared to the previous year.

The American Vietnamese Biotech EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-1.22 VND
Jan 1, 2018
2.21 VND
Jan 1, 2019
-3.83 VND
Jan 1, 2020
5.39 VND
Jan 1, 2021
-0.75 VND
Jan 1, 2022
-1.15 VND
Jan 1, 2023
-2.75 VND
Jan 1, 2024
0.72 VND
The American Vietnamese Biotech EV/FCF history
YEAREV/FCFYoY
0.72-126.25%
-2.75+138.01%
-1.15+53.26%
-0.75-113.96%
5.39-240.83%
-3.83-273.68%
2.21-280.93%
-1.22-100.89%
136.30—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Vietnamese Biotech Stock analysis

What does American Vietnamese Biotech do? American Vietnamese Biotech, Inc. generates revenue through the manufacture and distribution of high-tech medical diagnostics devices and equipment, including rapid diagnostic tests and ELISA kits. The company also produces medicines, vaccines, biological products, and cosmetic, soap, detergent, and cleaning products. Its subsidiary, American - Vietnamese Biology Company Limited, supports these manufacturing operations. The primary buyers are healthcare providers, laboratories, and distributors within the medical and pharmaceutical sectors, as well as consumers purchasing personal care items. The firm's financial investment activities and real estate trading contribute to additional revenue streams, though these are secondary to its core medical product manufacturing. The company's product portfolio targets both B2B segments in healthcare and B2C segments for consumer goods, with a focus on diagnostic tools and personal care solutions. As of 2012, the subsidiary structure remains central to its operational model. American Vietnamese Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Vietnamese Biotech stock

EV/FCF (Enterprise Value to Free Cash Flow) of American Vietnamese Biotech is 0.72 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of American Vietnamese Biotech changed from -2.75 to 0.72, representing a -126.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) American Vietnamese Biotech since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s American Vietnamese Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — American Vietnamese Biotech

All Key Metrics — American Vietnamese Biotech